Richard C Chou1,2, Michael Kane3,4, Sanjay Ghimire5, Shiva Gautam4,6, Jiang Gui7,8,9. 1. Section of Rheumatology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA. Richard.c.chou@dartmouth.edu. 2. Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. Richard.c.chou@dartmouth.edu. 3. Division of Rheumatology, Massachusetts General Hospital, Boston, MA, USA. 4. Department of Medicine, Harvard Medical School, Boston, MA, USA. 5. Verisk Health, Waltham, MA, USA. 6. Harvard CTSC Biostatistics Program, Beth Israel Deaconess Medical Center, Boston, MA, USA. 7. Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. 8. Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. 9. The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA.
Abstract
INTRODUCTION: It is increasingly becoming accepted that inflammation may play an important role in the pathogenesis of Alzheimer's disease (AD), as several immune-related genes have been associated with AD. Among these is tumor necrosis factor (TNF)-α, a proinflammatory cytokine known to play an important role in autoimmune disorders, including rheumatoid arthritis (RA). Although AD and RA appear to involve similar pathological mechanisms through the production of TNF-α, the relationship between AD and RA remains unknown. OBJECTIVE: To determine the relative risk of AD among RA patients and non-RA patients, and whether anti-TNF therapy for RA was associated with a lower risk of AD in RA patients. METHODS: We performed a nested case-control study of more than 8.5 million commercially insured adults (aged ≥18 years) in all 50 US states, Puerto Rico, and US Virgin Islands in the Verisk Health claims database. We derived a sub-cohort of subjects with a diagnosis of RA (controls), or RA and AD (cases), matching cases and controls based on age, sex, exposure assessment period, and methotrexate treatment. We also assessed relative risk of AD following exposure to standard RA therapies, including anti-TNF agents (infliximab, adalimumab, etanercept), methotrexate, prednisone, sulfasalazine, and rituximab. Odds ratios were adjusted for comorbidities, including coronary artery disease, diabetes mellitus, and peripheral vascular disease. RESULTS: AD was more prevalent (p < 0.0001) among RA patients (0.79 %) than among those without RA (0.11 %). Chronic conditions such as coronary artery disease (odds ratio [OR] 1.48; 95 % confidence interval [CI] 1.04-2.05; p = 0.03), diabetes (OR 1.86; 95 % CI 1.32-2.62; p = 0.0004), and peripheral vascular disease (OR 1.61; 95 % CI 1.06-2.43; p = 0.02) significantly increased the relative risk of AD among RA patients. Exposure to anti-TNF agents as a class, but not other immunosuppressive drugs studied, was associated with lowered risk of AD among RA patients (unadjusted OR 0.44; 95 % CI 0.22-0.87; p = 0.02; adjusted OR 0.45; 95 % CI 0.23-0.90; p = 0.02). Sub-group analysis demonstrated that of the three anti-TNF agents studied, only etanercept (unadjusted OR, 0.33; 95 % CI 0.08-0.94; p = 0.03; adjusted OR 0.30; 95 % CI 0.08-0.89; p = 0.02) was associated with a decreased risk of AD in RA patients. CONCLUSION: There is an increased risk of AD in the studied RA population. The relative risk of AD among RA subjects was lowered in those exposed to etanercept. Anti-TNF therapy with etanercept shows promise as a potential treatment for AD.
INTRODUCTION: It is increasingly becoming accepted that inflammation may play an important role in the pathogenesis of Alzheimer's disease (AD), as several immune-related genes have been associated with AD. Among these is tumor necrosis factor (TNF)-α, a proinflammatory cytokine known to play an important role in autoimmune disorders, including rheumatoid arthritis (RA). Although AD and RA appear to involve similar pathological mechanisms through the production of TNF-α, the relationship between AD and RA remains unknown. OBJECTIVE: To determine the relative risk of AD among RApatients and non-RApatients, and whether anti-TNF therapy for RA was associated with a lower risk of AD in RApatients. METHODS: We performed a nested case-control study of more than 8.5 million commercially insured adults (aged ≥18 years) in all 50 US states, Puerto Rico, and US Virgin Islands in the Verisk Health claims database. We derived a sub-cohort of subjects with a diagnosis of RA (controls), or RA and AD (cases), matching cases and controls based on age, sex, exposure assessment period, and methotrexate treatment. We also assessed relative risk of AD following exposure to standard RA therapies, including anti-TNF agents (infliximab, adalimumab, etanercept), methotrexate, prednisone, sulfasalazine, and rituximab. Odds ratios were adjusted for comorbidities, including coronary artery disease, diabetes mellitus, and peripheral vascular disease. RESULTS:AD was more prevalent (p < 0.0001) among RApatients (0.79 %) than among those without RA (0.11 %). Chronic conditions such as coronary artery disease (odds ratio [OR] 1.48; 95 % confidence interval [CI] 1.04-2.05; p = 0.03), diabetes (OR 1.86; 95 % CI 1.32-2.62; p = 0.0004), and peripheral vascular disease (OR 1.61; 95 % CI 1.06-2.43; p = 0.02) significantly increased the relative risk of AD among RApatients. Exposure to anti-TNF agents as a class, but not other immunosuppressive drugs studied, was associated with lowered risk of AD among RApatients (unadjusted OR 0.44; 95 % CI 0.22-0.87; p = 0.02; adjusted OR 0.45; 95 % CI 0.23-0.90; p = 0.02). Sub-group analysis demonstrated that of the three anti-TNF agents studied, only etanercept (unadjusted OR, 0.33; 95 % CI 0.08-0.94; p = 0.03; adjusted OR 0.30; 95 % CI 0.08-0.89; p = 0.02) was associated with a decreased risk of AD in RApatients. CONCLUSION: There is an increased risk of AD in the studied RA population. The relative risk of AD among RA subjects was lowered in those exposed to etanercept. Anti-TNF therapy with etanercept shows promise as a potential treatment for AD.
Authors: S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin Journal: J Biol Chem Date: 1995-03-31 Impact factor: 5.157
Authors: Sebastian E Sattui; Mangala Rajan; Sarah B Lieber; Geyanne Lui; Madeline Sterling; Jeffrey R Curtis; Lisa A Mandl; Iris Navarro-Millán Journal: Semin Arthritis Rheum Date: 2021-01-05 Impact factor: 5.532
Authors: Melissa A Rosenkranz; Douglas C Dean; Barbara B Bendlin; Nizar N Jarjour; Stephane Esnault; Henrik Zetterberg; Amanda Heslegrave; Michael D Evans; Richard J Davidson; William W Busse Journal: J Allergy Clin Immunol Date: 2021-09-15 Impact factor: 10.793
Authors: Maria Vassilaki; Cynthia S Crowson; John M Davis Iii; Stephanie Q Duong; David T Jones; Aivi Nguyen; Michelle M Mielke; Prashanthi Vemuri; Elena Myasoedova Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas Journal: J Pharmacol Exp Ther Date: 2019-02-01 Impact factor: 4.030
Authors: David Furman; Judith Campisi; Eric Verdin; Pedro Carrera-Bastos; Sasha Targ; Claudio Franceschi; Luigi Ferrucci; Derek W Gilroy; Alessio Fasano; Gary W Miller; Andrew H Miller; Alberto Mantovani; Cornelia M Weyand; Nir Barzilai; Jorg J Goronzy; Thomas A Rando; Rita B Effros; Alejandro Lucia; Nicole Kleinstreuer; George M Slavich Journal: Nat Med Date: 2019-12-05 Impact factor: 53.440
Authors: Tamas Fulop; Shreyansh Tripathi; Serafim Rodrigues; Mathieu Desroches; Ton Bunt; Arnold Eiser; Francois Bernier; Pascale B Beauregard; Annelise E Barron; Abdelouahed Khalil; Adam Plotka; Katsuiku Hirokawa; Anis Larbi; Christian Bocti; Benoit Laurent; Eric H Frost; Jacek M Witkowski Journal: Neuropsychiatr Dis Treat Date: 2021-05-04 Impact factor: 2.570